Citation & Authors
Front Immunol. 2025;16:1744226.
ABSTRACT · CHINESE TRANSLATION
Translated abstract
Translated from the licensed abstract via the Chinese version. This is not an official journal translation.
purpose
Real-world data were used to compare the risk of systemic autoimmune diseases (SADs) in children with juvenile idiopathic arthritis (JIA) receiving TNF versus IL-6 inhibitors.
method
This retrospective cohort study used the TriNetX Research Network, which includes more than 122 million patients. It included patients aged ≤18 years with JIA who initiated TNF or IL-6 inhibitors between January 1, 2013, and December 31, 2024. Baseline characteristics were balanced by 1:1 propensity score matching. Incident SAD was the primary outcome; HRs were estimated using Cox models, and subgroup and sensitivity analyses evaluated robustness.
result
After matching, each group included 1,192 patients. SAD incidence was significantly lower with TNF inhibitors than with IL-6 inhibitors (17 versus 45 events; HR 0.37; 95% CI 0.20–0.63). Findings were consistent across strata defined by age, sex, and concomitant medications. Sensitivity analyses using three adjustment models supported robustness, with HRs ranging from 0.28–0.46.
Conclusion
In children with JIA, TNF inhibitors were associated with a substantially lower risk of systemic autoimmune diseases than IL-6 inhibitors. These findings may inform biologic selection and long-term safety considerations in pediatric rheumatology.
Original work: Author of the above paper. Source:Public Summary ↗. This translation is based on the Chinese rendering of the original English abstract.
Original work license:CC BY ↗;Translations are subject to the same licensing conditions.
